Showing results (121-130 of 159) with videos related to
Sort By:
Pageof 16
Molecular Cell|May 19, 2018
C-Terminal End-Directed Protein Elimination by CRL2 Ubiquitin LigasesHsiu-Chuan Lin, Chi-Wei Yeh, Yen-Fu Chen, et al.BMC Pulmonary Medicine|August 21, 2025
Comparing survival outcomes of anti-fibrotic therapy for idiopathic pulmonary fibrosis with and without emphysema: a multi-center real-world study from TaiwanYu-Hung Fang, Yi-An Hsieh, Yen-Fu Chen, et al.Scientific Reports|November 26, 2021
Fecal microbiota changes in NZB/W F1 mice after induction of lupus diseaseYen-Fu Chen, Ao-Ho Hsieh, Lian-Chin Wang, et al.Lancet (London, England)|October 21, 2016
The history, geography, and sociology of slums and the health problems of people who live in slumsAlex Ezeh, Oyinlola Oyebode, David Satterthwaite, et al.Antiviral Research|November 19, 2008
Aurintricarboxylic acid inhibits influenza virus neuraminidaseHui-Chen Hung, Ching-Ping Tseng, Jinn-Moon Yang, et al.BMC Medicine|March 15, 2025
Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancerShao-Jing Wang, Lou Sun, Yu-Hsiang Shih, et al.BMJ Open|June 6, 2019
Magnitude and modifiers of the weekend effect in hospital admissions: a systematic review and meta-analysisYen-Fu Chen, Xavier Armoiry, Caroline Higenbottam, et al.Journal of Clinical Medicine|October 16, 2024
Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus PaclitaxelShao-Jing Wang, Hsin-Hua Chen, Lou Sun, et al.Frontiers in Oncology|December 13, 2023
Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcomaSzu-Yun Niu, Lou Sun, Shih-Tien Hsu, et al.Lancet (London, England)|October 21, 2016
Improving the health and welfare of people who live in slumsRichard J Lilford, Oyinlola Oyebode, David Satterthwaite, et al.Pageof 16